newsfilter
← Latest News
Business Wire·

Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™

John Knighton to join Sesen Bio as Vice President and Chief Compliance Officer The Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developin